ASSERTIO HOLDINGS INC (ASRT) Stock Fundamental Analysis
USA - NASDAQ:ASRT - US04546C2052 - Common Stock
0.75 USD
-0.04 (-5.18%)
0.7612 USD
+0.01 (+1.49%)
Taking everything into account, ASRT scores 3 out of 10 in our fundamental rating. ASRT was compared to 192 industry peers in the Pharmaceuticals industry. ASRT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ASRT is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ASRT had negative earnings in the past year.
ASRT had a positive operating cash flow in the past year.
ASRT had negative earnings in 4 of the past 5 years.
Of the past 5 years ASRT 4 years had a positive operating cash flow.
1.2 Ratios
ASRT's Return On Assets of -15.66% is fine compared to the rest of the industry. ASRT outperforms 61.46% of its industry peers.
With a Return On Equity value of -46.15%, ASRT perfoms like the industry average, outperforming 54.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.66% | ||
| ROE | -46.15% | ||
| ROIC | N/A |
ROA(3y)-32.44%
ROA(5y)-21.4%
ROE(3y)-70.07%
ROE(5y)-52.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ASRT has a better Gross Margin (67.87%) than 75.52% of its industry peers.
ASRT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ASRT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.36%
GM growth 5Y-6.47%
2. Health
2.1 Basic Checks
ASRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ASRT has more shares outstanding
ASRT has more shares outstanding than it did 5 years ago.
ASRT has a worse debt/assets ratio than last year.
2.2 Solvency
ASRT has an Altman-Z score of -2.95. This is a bad value and indicates that ASRT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ASRT (-2.95) is comparable to the rest of the industry.
The Debt to FCF ratio of ASRT is 2.22, which is a good value as it means it would take ASRT, 2.22 years of fcf income to pay off all of its debts.
ASRT's Debt to FCF ratio of 2.22 is amongst the best of the industry. ASRT outperforms 92.19% of its industry peers.
ASRT has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
ASRT has a Debt to Equity ratio (0.42) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 2.22 | ||
| Altman-Z | -2.95 |
ROIC/WACCN/A
WACC8.89%
2.3 Liquidity
ASRT has a Current Ratio of 1.58. This is a normal value and indicates that ASRT is financially healthy and should not expect problems in meeting its short term obligations.
ASRT has a worse Current ratio (1.58) than 68.75% of its industry peers.
A Quick Ratio of 1.33 indicates that ASRT should not have too much problems paying its short term obligations.
The Quick ratio of ASRT (1.33) is worse than 68.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.33 |
3. Growth
3.1 Past
ASRT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.60%, which is quite impressive.
Looking at the last year, ASRT shows a very negative growth in Revenue. The Revenue has decreased by -17.83% in the last year.
Measured over the past years, ASRT shows a very negative growth in Revenue. The Revenue has been decreasing by -11.45% on average per year.
EPS 1Y (TTM)72.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%500%
Revenue 1Y (TTM)-17.83%
Revenue growth 3Y4.03%
Revenue growth 5Y-11.45%
Sales Q2Q%69.36%
3.2 Future
Based on estimates for the next years, ASRT will show a very strong growth in Earnings Per Share. The EPS will grow by 35.53% on average per year.
Based on estimates for the next years, ASRT will show a small growth in Revenue. The Revenue will grow by 4.54% on average per year.
EPS Next Y-105.11%
EPS Next 2Y1.21%
EPS Next 3Y33.04%
EPS Next 5Y35.53%
Revenue Next Year-8.53%
Revenue Next 2Y-2.42%
Revenue Next 3Y2.76%
Revenue Next 5Y4.54%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ASRT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASRT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, ASRT is valued cheaper than 95.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.11 | ||
| EV/EBITDA | -24.64 |
4.3 Compensation for Growth
ASRT's earnings are expected to grow with 33.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.21%
EPS Next 3Y33.04%
5. Dividend
5.1 Amount
No dividends for ASRT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.75
-0.04 (-5.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners26.95%
Inst Owner Change0.5%
Ins Owners1.37%
Ins Owner Change3.98%
Market Cap72.18M
Revenue(TTM)124.96M
Net Income(TTM)-42.92M
Analysts82
Price Target2.72 (262.67%)
Short Float %4.38%
Short Ratio17.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-42.33%
Min EPS beat(2)-119.3%
Max EPS beat(2)34.64%
EPS beat(4)2
Avg EPS beat(4)-48.42%
Min EPS beat(4)-145.1%
Max EPS beat(4)36.06%
EPS beat(8)2
Avg EPS beat(8)-484.65%
EPS beat(12)4
Avg EPS beat(12)-320.69%
EPS beat(16)7
Avg EPS beat(16)-209.36%
Revenue beat(2)1
Avg Revenue beat(2)-1.4%
Min Revenue beat(2)-5.64%
Max Revenue beat(2)2.84%
Revenue beat(4)2
Avg Revenue beat(4)1.6%
Min Revenue beat(4)-5.64%
Max Revenue beat(4)10.04%
Revenue beat(8)4
Avg Revenue beat(8)-2.43%
Revenue beat(12)8
Avg Revenue beat(12)0.26%
Revenue beat(16)12
Avg Revenue beat(16)2.45%
PT rev (1m)0%
PT rev (3m)-4.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-32.81%
EPS NY rev (1m)0%
EPS NY rev (3m)-46.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.79%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.62 | ||
| P/FCF | 4.11 | ||
| P/OCF | 4.11 | ||
| P/B | 0.77 | ||
| P/tB | 2.26 | ||
| EV/EBITDA | -24.64 |
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)0.18
FCFY24.31%
OCF(TTM)0.18
OCFY24.31%
SpS1.22
BVpS0.98
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.66% | ||
| ROE | -46.15% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.87% | ||
| FCFM | 14.99% |
ROA(3y)-32.44%
ROA(5y)-21.4%
ROE(3y)-70.07%
ROE(5y)-52.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.36%
GM growth 5Y-6.47%
F-Score3
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 2.22 | ||
| Debt/EBITDA | 28.14 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 1266.23% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.33 | ||
| Altman-Z | -2.95 |
F-Score3
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)16.82%
Cap/Depr(5y)10.16%
Cap/Sales(3y)3.56%
Cap/Sales(5y)2.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%500%
EPS Next Y-105.11%
EPS Next 2Y1.21%
EPS Next 3Y33.04%
EPS Next 5Y35.53%
Revenue 1Y (TTM)-17.83%
Revenue growth 3Y4.03%
Revenue growth 5Y-11.45%
Sales Q2Q%69.36%
Revenue Next Year-8.53%
Revenue Next 2Y-2.42%
Revenue Next 3Y2.76%
Revenue Next 5Y4.54%
EBIT growth 1Y-79.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year198.92%
EBIT Next 3Y64.36%
EBIT Next 5Y43.58%
FCF growth 1Y-71.51%
FCF growth 3Y68.86%
FCF growth 5Y-21.82%
OCF growth 1Y-77.5%
OCF growth 3Y67.83%
OCF growth 5Y-22.08%
ASSERTIO HOLDINGS INC / ASRT FAQ
Can you provide the ChartMill fundamental rating for ASSERTIO HOLDINGS INC?
ChartMill assigns a fundamental rating of 3 / 10 to ASRT.
Can you provide the valuation status for ASSERTIO HOLDINGS INC?
ChartMill assigns a valuation rating of 2 / 10 to ASSERTIO HOLDINGS INC (ASRT). This can be considered as Overvalued.
How profitable is ASSERTIO HOLDINGS INC (ASRT) stock?
ASSERTIO HOLDINGS INC (ASRT) has a profitability rating of 2 / 10.
What is the financial health of ASSERTIO HOLDINGS INC (ASRT) stock?
The financial health rating of ASSERTIO HOLDINGS INC (ASRT) is 4 / 10.
Can you provide the expected EPS growth for ASRT stock?
The Earnings per Share (EPS) of ASSERTIO HOLDINGS INC (ASRT) is expected to decline by -105.11% in the next year.